SecBot SecBot
424B5 ·Filed Jun 24, 2026

QURE

uniQure N.V.
MIXED
Impact 6/10
Horizonweeks Processed4mo ago SEC0001104659-26-077336
Notable filing: 424B5
Actionable Insight ◆ Mixed

The offering removes near-term financing risk and funds the critical BLA submission for AMT-130, but the 7.8% dilution and 7.2% discount create immediate selling pressure. Watch for the BLA submission in Q3 2026 and any updates on confirmatory study alignment with FDA. The stock's recent run-up (+60% in prior week per historical data) suggests the offering may have been anticipated; the discount may trigger profit-taking in the near term.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+20
Entry
$49.10
T+0 close · Jun 24, 2026 · via day close
Latest settled
−19.69%
T+20 · $39.43
Vs SPY
−20.22%
α at T+20
Next horizon
T+60
due 8w ago
  1. T+0 · Jun 25 $49.10entry
  2. T+1 · 5mo ago −3.24%α −2.52% · $47.51
  3. T+5 · 5mo ago −8.00%α −9.56% · $45.17
  4. T+20 · 4mo ago −19.69%α −20.22% · $39.43
  5. T+60 · due 8w ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

uniQure priced a $225M underwritten public offering of 4,945,055 ordinary shares at $45.50/share, a ~7.2% discount to the prior close of $49.04. Net proceeds of ~$211M will fund commercialization readiness, a confirmatory study for lead gene therapy AMT-130 (Huntington's disease), and pipeline development. The offering comes days after the company announced FDA alignment to accept Phase I/II data as the primary basis for a BLA submission under accelerated approval, a major regulatory de-risking event. The 7.8% dilution (4.95M new shares vs 63.0M outstanding) is a near-term overhang, but the capital raise removes a key financing overhang and funds the path to a pivotal BLA filing in Q3 2026.

Key Facts

  • Offering of 4,945,055 ordinary shares at $45.50/share, raising ~$225M gross / ~$211M net proceeds
  • Underwriters have a 30-day option to purchase up to an additional 741,758 shares
  • Public offering price represents a ~7.2% discount to the June 23, 2026 close of $49.04
  • Post-offering shares outstanding: 67,978,304 (68,720,062 if underwriters exercise option in full), a ~7.8% increase from 63,033,249
  • Net proceeds of ~$211M will fund AMT-130 commercialization readiness, confirmatory study, pipeline development, and general corporate purposes
  • On June 17, 2026, uniQure announced FDA alignment to accept Phase I/II data as primary basis for BLA under accelerated approval, with submission planned for Q3 2026
  • Immediate dilution of $41.72 per share for new investors (public offering price of $45.50 vs. as-adjusted net tangible book value of $3.78)
  • Lock-up agreements restrict insider sales for 60 days post-offering

Financial Impact

~$211M net capital infusion (~$242.7M if greenshoe exercised), representing ~6.8% of pre-offering market cap of $3.1B. Dilution of ~7.8% to existing shareholders.

dilutioncashshares outstanding

Risk Factors

  • Dilution of ~7.8% from new shares, with potential for further dilution if underwriters exercise greenshoe
  • BLA submission and accelerated approval for AMT-130 remain subject to FDA alignment on confirmatory study design and acceptance of Phase I/II data
  • Pre-revenue biotech with no approved products; commercialization and pipeline execution risk
  • PFIC status risk for U.S. holders could create adverse tax consequences
  • Stock volatility expected given limited trading volume and binary regulatory catalysts

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
76% bullish (21 analysts)

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (Primary)0001104659-26-077336
Document: tm2618428d2_ex-filingfees.htm0001104659-26-077336
Document: 0001104659-26-077336-index-headers.html0001104659-26-077336
Document: 0001104659-26-077336-index.html0001104659-26-077336
Document: 0001104659-26-077336.txt0001104659-26-077336

Track record

38 reports on QURE

Performance horizon

6 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +27.15% at T+20 after the Jul 29, 2026 report. 8 of 11 went positive at some point.

Filters
  1. Nov 6, 202610d ago 144 Neutral 2/10 Entry $22.79 to $22.71 Now $21.88 −3.99% ▼ −0.35% +0.02% vs SPY
  2. Nov 4, 202612d ago 8-K Bullish 7/10 No price data
  3. Nov 4, 202612d ago Press Release Neutral 6/10 Entry $23.03 to $21.01 Now $21.88 −4.99% ▼ −8.77% −4.36% vs SPY
  4. Nov 2, 202614d ago 8-K Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  5. Nov 2, 202614d ago Press Release Bullish 7/10 Entry $22.97 to $23.87 Now $21.88 −4.75% ▲ +3.92% +3.62% vs SPY
  6. Oct 16, 20264w ago SC 13G/A Neutral 3/10 Entry $21.78 to $22.20 Now $21.88 +0.46% ▲ +1.93% +1.51% vs SPY
  7. Sep 2, 202610w ago 8-K Bullish 7/10 Entry $46.23 to $44.86 Now $21.88 −52.67% ▼ −2.96% −4.01% vs SPY
  8. Jul 29, 202615w ago 8-K Bullish 8/10 Entry $40.07 to $42.19 Now $21.88 −45.40% ▲ +5.29% +3.61% vs SPY
  9. Jul 7, 202619w ago Insider Cluster Bearish 5/10 Entry $41.41 to $43.49 Now $21.88 +47.16% ▼ −5.02% −5.33% vs SPY
  10. Jul 2, 202619w ago Insider Cluster Bearish 4/10 Entry $41.81 to $41.36 Now $21.88 +47.67% ▲ +1.08% +1.95% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (10h 8m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 24, 2026